Date: 2014-09-02
Type of information: Financing round
Company: Affimed (Germany)
Investors:
Amount: $29.7 million (€22.2 million)
Funding type: series E financing round, loan
Planned used: This funding is dedicated to the continued clinical development of Affimed’s cancer immunotherapies. Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.
Others: * On September 2, 2014, Affimed Therapeutics announced that it has closed a $15.7 million (€11.7 million) Series E equity funding led by Affimed’s current investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed. In addition, the Company has signed a $14 million (€10.5 million) loan agreement with Perceptive Advisors, leading to a total of $29.7 million (€22.2 million) in committed financing, with $11 million (€8.2 million) of the Series E and $5.5 million (€4.1 million) of the loan already invested.
Therapeutic area: Cancer - Oncology
